For agency owners, business coaches and strategic consultants, it pays to be a better speaker. Public speaking is clearly the top strategy for attracting new clients. So, take a lesson from Cyril ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Milwaukee charter school Pathways High is expanding to include sixth through eighth grades next fall. Pathways High offers unique classes in subjects like robotics and boat building, often in ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

The FDA has released draft guidance outlining an approval pathway for individualized therapies aimed at ultra-rare diseases, building on a framework first outlined by agency leaders in November. The ...

Oilsands producers and the Alberta and federal governments are stepping up talks ahead of an April 1 deadline for a deal tying a major carbon capture proposal to expanded crude production and a new ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...